Piper Jaffray Companies set a $52.00 price target on Adamas Pharmaceuticals (NASDAQ:ADMS) in a report issued on Tuesday. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.
Other equities analysts also recently issued research reports about the company. Northland Securities began coverage on Adamas Pharmaceuticals in a research report on Wednesday, November 29th. They set an outperform rating on the stock. Mizuho reiterated a buy rating and set a $26.00 price target on shares of Adamas Pharmaceuticals in a research report on Tuesday, September 5th. Cowen set a $55.00 price target on Adamas Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, December 13th. Zacks Investment Research upgraded Adamas Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday, September 21st. Finally, BidaskClub cut Adamas Pharmaceuticals from a buy rating to a hold rating in a report on Thursday, December 14th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $45.67.
Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) traded up $2.04 during mid-day trading on Tuesday, reaching $34.27. The company’s stock had a trading volume of 868,100 shares, compared to its average volume of 552,187. The company has a current ratio of 8.35, a quick ratio of 8.32 and a debt-to-equity ratio of 0.41. Adamas Pharmaceuticals has a 52 week low of $13.50 and a 52 week high of $38.22.
Several institutional investors have recently made changes to their positions in ADMS. Macquarie Group Ltd. acquired a new position in shares of Adamas Pharmaceuticals during the third quarter valued at approximately $15,899,000. Point72 Asset Management L.P. raised its holdings in shares of Adamas Pharmaceuticals by 639.3% during the third quarter. Point72 Asset Management L.P. now owns 850,165 shares of the specialty pharmaceutical company’s stock valued at $17,998,000 after acquiring an additional 735,165 shares during the last quarter. Axiom International Investors LLC DE raised its holdings in shares of Adamas Pharmaceuticals by 134.1% during the third quarter. Axiom International Investors LLC DE now owns 236,209 shares of the specialty pharmaceutical company’s stock valued at $5,001,000 after acquiring an additional 135,297 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Adamas Pharmaceuticals by 13,028.4% during the third quarter. JPMorgan Chase & Co. now owns 136,273 shares of the specialty pharmaceutical company’s stock valued at $2,839,000 after acquiring an additional 135,235 shares during the last quarter. Finally, EAM Investors LLC acquired a new position in shares of Adamas Pharmaceuticals during the third quarter valued at approximately $1,795,000. 79.40% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Piper Jaffray Companies Analysts Give Adamas Pharmaceuticals (ADMS) a $52.00 Price Target” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.com-unik.info/2017/12/22/piper-jaffray-companies-analysts-give-adamas-pharmaceuticals-adms-a-52-00-price-target.html.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
What are top analysts saying about Adamas Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Adamas Pharmaceuticals and related companies.